Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$86.88 USD
+2.51 (2.97%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $86.88 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LGND 86.88 +2.51(2.97%)
Will LGND be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LGND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LGND
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
LGND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Other News for LGND
Ligand Pharma’s Growth Outlook Bolstered by COPD Drug Approval and Strategic Oncology Royalty Deal
Craig-Hallum Sticks to Their Buy Rating for Ligand Pharma (LGND)
Ligand earns $5.8M milestone payment following FDA approval of Ohtuvayre
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
Ligand collaborator Merck receives FDA approval for CAPVAXIVE